EMPA-REG OUTCOME: The Nephrologist's Point of View

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Increasing evidence suggests sodium glucose cotransporter 2 (SGLT2) inhibitors possess renoprotective properties.
• Renal analyses from major clinical trials support these beneficial effects in patients with type 2 diabetes.

Purpose of the Study:

• To review renal outcomes data from key SGLT2 inhibitor clinical trials.
• To discuss proposed mechanisms underlying SGLT2 inhibitor-associated renoprotection.
• To consider important renal safety aspects of SGLT2 inhibitor therapy.

Main Methods:

• Review of renal outcome data from pivotal SGLT2 inhibitor trials (e.g., EMPA-REG OUTCOME, CANTATA-SU).
• Analysis of postulated mechanisms, including direct renovascular and hemodynamic effects.
• Evaluation of reported renal safety data associated with SGLT2 inhibitors.

Main Results:

• Clinical trials demonstrate significant renal benefits associated with SGLT2 inhibitors.
• Potential renoprotective mechanisms are multifactorial, with hemodynamic effects playing a key role.
• Key renal safety considerations have been identified for SGLT2 inhibitor use.

Conclusions:

• SGLT2 inhibitors exhibit notable renoprotective effects in patients with type 2 diabetes.
• Understanding the mechanisms and safety profile is crucial for optimizing renal outcomes.
• Further research continues to elucidate the full scope of SGLT2 inhibitor benefits for kidney health.